Argentine GMP Guide for Medicines
Argentina’s consolidated GMP guide for manufacturers and importers/exporters of human-use medicines, signed 13 June 2023 and published in the Boletín Oficial on 16 June 2023. Its recitals name the sources it adopts rather than gesturing at them: **PIC/S PE 009-16 Parts I and II (2022)** and **ICH Q7A**, alongside WHO and ISO guidance. That named version matters — Argentina pins PE 009-16 where Australia’s Manufacturing Principles pin PE 009-17, so “PIC/S-aligned” is not one standard across jurisdictions.
What this does not cover
stated in the document's own scope- Covers GMP for medicines for human use; other product classes and active pharmaceutical ingredients are the subject of ANMAT’s separate dispositions.
- Sets manufacturing GMP, not the product-registration pathway, which ANMAT governs through distinct registration rules.
- Is the general GMP requirement; specific dosage forms or technologies may carry additional ANMAT normative provisions.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Disposición ANMAT 4159/2023 is Argentina’s current Good Manufacturing Practices guide for medicines for human use, applying to manufacturers and to importers and exporters. It consolidates and replaces a string of earlier dispositions — 2819/04, 3602/18, 3827/18 and 1281/19 — into a single up-to-date GMP text, so a manufacturer no longer has to reconcile several overlapping instruments. Its content is built on WHO, PIC/S, ICH and ISO guidance, covering the pharmaceutical quality system, personnel, premises and equipment, documentation, production, quality control, qualification and validation, and outsourced activities in the familiar chapter-and-annex form used internationally.
Scope & applicability
Manufacturers and importers/exporters of human-use medicines subject to Argentine sanitary police power. The chain of authority runs Ley 16.463 → Decreto Reglamentario 9763/1964 → Decreto 1490/1992, which created ANMAT as a decentralised body with financial autarky and jurisdiction across the whole national territory; the disposition binds interprovincial trade and import/export as well as activity in the federal capital.
Legal basis & how it acquires force
The guide is a Disposición of ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), Argentina’s national medicines, food and medical-technology authority, issued under its enabling legislation. As an ANMAT disposition it carries the force of regulation for the Argentine market: a manufacturing or importing site must comply to hold the GMP authorisation ANMAT requires. Compliance is tied to that authorisation rather than being an advisory recommendation, which is why the text reads as binding requirements rather than as guidance.
Document structure
| Part | Covers |
|---|---|
| Pharmaceutical quality system | Quality management, quality risk management, and product quality review |
| Personnel and premises | Personnel, training, hygiene, and facility and equipment requirements |
| Documentation | The documentation system, records, and data controls |
| Production and quality control | Manufacturing operations, in-process control, and the quality-control laboratory |
| Qualification and validation | Qualification of facilities and equipment and process, cleaning, and analytical validation |
| Complaints, recalls, and outsourcing | Complaint handling, recall, self-inspection, and contracted activities |
Quick reference · What Disposición 4159/2023 actually does
Four short articles carry the whole reform. The GMP requirements themselves are in the annex, not in the disposition — cite the annex reference when you are asked for the source.
- Art. 1 — approves the guide — The “Guía de Buenas Prácticas de Fabricación para Elaboradores, Importadores/Exportadores de Medicamentos de Uso Humano”, annexed as DI-2023-64216567-APN-INAME#ANMAT and an integral part of the disposition
- Art. 2 — repeals four dispositions — ANMAT Dispositions 2819/04, 3602/18, 3827/18 and 1281/19 are revoked outright, not amended
- Art. 3 — deferred commencement — In force 30 business days (días hábiles) after publication in the Boletín Oficial — not on publication
- Art. 4 — notification — Communicated to the industry chambers (CILFA, CAEME, COOPERALA, CAPGEN, CAPEMVeL, CAPDROFAR, CAB, SAFYBI, COMRA, COFA)
The annex is authored by INAME, the Instituto Nacional de Medicamentos — which is also the entity PIC/S registers as Argentina’s participating authority, not ANMAT as a whole.
Source: Disposición ANMAT 4159/2023, signed 13 June 2023, Boletín Oficial 16 June 2023. Verify against the current text before relying on it for a submission.
Key requirements
- Apply the annexed GMP guide (DI-2023-64216567-APN-INAME#ANMAT), which is an integral part of the disposition
- Work to PIC/S PE 009-16 Parts I and II as the adopted international baseline, with ICH Q7A for active substances
- Hold ANMAT authorisation for the establishment and expect technical inspection of operating conditions and quality-control systems
- Treat the four repealed dispositions as void — 2819/04, 3602/18, 3827/18 and 1281/19 no longer state any requirement
Implementation tips
- Do not date compliance from publication: Article 3 sets commencement 30 business days after the Boletín Oficial entry, so the obligation and the publication date are different dates
- Cite the annex identifier DI-2023-64216567-APN-INAME#ANMAT when asked for the GMP source — the disposition text itself contains no GMP requirements
- Check your PE 009 baseline before claiming alignment: an EU or Australian system built on PE 009-17 exceeds what Argentina adopted, which is fine, but the reverse gap is not
- Argentina is a PIC/S participating authority (acceded January 2008), registered by PIC/S as the Instituto Nacional de Medicamentos (INAME) rather than as ANMAT
Revision notes
Signed 13 June 2023 and published in the Boletín Oficial on 16 June 2023, after the draft was put to public consultation. Article 2 repeals Dispositions 2819/04, 3602/18, 3827/18 and 1281/19; Article 3 defers commencement to 30 business days after publication. The recitals give the reason for the recast: adopting the newer international requirements, specifically PIC/S PE 009-16 Parts I and II of 2022 and ICH Q7A.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Argentina (ANMAT) has been a PIC/S participating authority since 2008, and Disposición 4159/2023 is expressly built on WHO, PIC/S, ICH and ISO guidance — so the requirements track the PIC/S GMP Guide, which itself mirrors EU GMP. That convergence is the intent: it keeps Argentine GMP comparable with the international standard while the legal obligation remains the ANMAT disposition applied domestically.
ANMAT Disposición 4159/2023: frequently asked questions
Quick answers to common questions about ANMAT Disposición 4159/2023.
What earlier rules did ANMAT Disposición 4159/2023 replace?
It consolidates and replaces the earlier GMP dispositions 2819/04, 3602/18, 3827/18 and 1281/19 into a single current text, built on WHO, PIC/S, ICH and ISO guidance.
Is Argentina a PIC/S member?
Yes. ANMAT has been a PIC/S participating authority since 2008, which is why Disposición 4159/2023 is harmonised with the PIC/S GMP Guide — the guide that itself mirrors EU GMP.
Who issues and enforces this GMP guide?
ANMAT — Argentina’s national medicines, food and medical-technology administration — issues it as a binding disposition and applies it when authorising manufacturing and importing sites for the Argentine market.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.